First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment (FINELAND)

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment: A Phase 2 FINELAND Trial

This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.

Study Overview

• Status: Not yet recruiting
• Conditions: Advanced Hepatocellular Carcinoma
• Intervention / Treatment: Drug: Lenvatinib

Detailed Description

<Treatment Phase> All participants will receive lenvatinib treatment after signing informed consent. Lenvatinib will be administered orally once daily at a dose of 8 mg, at the same time each day, with or without food.

Treatment must begin within 3 days after screening and will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

<Follow-up Phase> After the treatment phase, participants will be followed every 12 weeks (±7 days) after the last dose for survival status and use of subsequent anticancer therapies. Survival follow-up will be conducted for at least 12 months after enrollment of the last participant.

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Yoonsun Kim; Phone Number: +82-10-4795-4675; Email: eda0208@ncc.re.kr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed informed consent
2. Age ≥ 19 years at the time of signing informed consent
3. Histological or clinical diagnosis of HCC according to the Korean Liver Cancer Association-National Cancer Center guidelines
4. HCC not amenable to curative treatment (e.g., surgical resection, local therapy, liver transplantation)

5. At least one measurable target lesion according to RECIST v1.1

   - Participants who previously received local treatment (e.g., radiofrequency ablation, microwave ablation, transarterial chemoembolization, transarterial radioembolization, transarterial embolization, or radiotherapy) are eligible if (a) target lesions have not been treated by prior local therapy, or (b) lesions within the field of local therapy have subsequently progressed according to RECIST v1.1.

6. Child-Pugh class B7-B8
7. ECOG performance status (PS) 0-2

8. Adequate hematologic and end-organ function defined by the following laboratory tests obtained within 14 days prior to screening:

   • Hemoglobin ≥ 8.0g/dL
   • Absolute neutrophil count (ANC) ≥ 1,000/mm3
   • Platelet count ≥ 50,000/μL
   • Total bilirubin < 3.5 mg/dL
   • Serum albumin ≥ 2.5 g/dL
   • ALT and AST ≤ 7 x upper limit of normal (ULN)
   • Prothrombin time (INR ≤ 1.8 × ULN)
   • Serum creatinine ≤ 2.0 × ULN or calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault equation)

9. Documented virological status for hepatitis B virus (HBV) and hepatitis C virus (HCV) by screening tests.

   - Participants with HBV or HCV infection must receive antiviral therapy in accordance with institutional guidelines.

10. Women of childbearing potential must agree to remain abstinent or use effective contraception (failure rate < 1% per year) from signing informed consent through at least 6 months after the last study drug administration.

Men must agree to remain abstinent or use effective contraception (failure rate < 1% per year) during the same period and refrain from sperm donation.

Exclusion Criteria:

1. Fibrolamellar carcinoma or sarcomatoid carcinoma
2. Prior systemic therapy for HCC

3. Local therapy for HCC (including radiofrequency ablation, microwave ablation, cryoablation, transarterial chemoembolization, radioembolization, or radiotherapy) within 28 days prior to initiation of study treatment, or unresolved complications from such procedures

   - Palliative radiotherapy to bone lesions is permitted with a 7-day washout

4. History of allogeneic stem cell or solid organ transplantation
5. Active brain metastases or leptomeningeal disease
6. History of another malignancy within 2 years prior to screening, except for cancers with negligible risk of metastasis or death (e.g., >90% 5-year survival)
7. Serious uncontrolled medical comorbidities within 3 months prior to study treatment, including severe cardiovascular disease (NYHA class ≥ II heart disease, myocardial infarction, or cerebrovascular accident), unstable arrhythmia, or unstable angina, or any condition judged by the investigator to increase participant risk
8. Pregnant or breastfeeding women, or men and women of reproductive potential unwilling to use effective contraception from screening through 6 months after the last study drug administration
9. Any condition judged by the investigator to interfere with compliance with study procedures, restrictions, or requirements

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Lenvatinib; Lenvatinib will be administered orally once daily at a dose of 8 mg, at the same time each day, with or without food. Treatment must begin within 3 days after screening and will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

Drug: Lenvatinib; Lenvatinib will be administered orally at a dose of 8 mg once daily at the same time each day, with or without food (regardless of body weight). For participants with a baseline body weight ≥60 kg who tolerate lenvatinib at 8 mg once daily (i.e., experiencing only Grade 1 or lower adverse events) and have maintained this dose for at least 2 weeks, the daily dose of lenvatinib may be increased to 12 mg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS)	Progression-free survival (PFS) is defined as the time from the date of treatment initiation to the date of first documented progressive disease (PD) according to RECIST v1.1, as assessed by the investigator, or death from any cause.	Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	Overall survival (OS) is defined as the time from the date of treatment initiation to death from any cause.	Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred
Time to progression (TTP)	Time to progression (TTP) is defined as the time from the date of treatment initiation to the date of first documented progressive disease (PD) according to RECIST v1.1, as assessed by the investigator.	Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.
Objective response rate (ORR)	Objective response rate (ORR) is defined as the proportion of participants whose best overall response is complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1.	Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.
Disease control rate (DCR)	Disease control rate (DCR) is defined as the proportion of participants whose best overall response is complete CR, PR, or stable disease (SD), as assessed by the investigator according to RECIST v1.1.	Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.
The incidence of AEs	The incidence of AEs is defined as the number of all AEs occurring in participants from the first dose of the investigational product until the last follow-up visit, as well as the proportion of participants who experience them. The severity of AEs will be graded on a scale of Grade 1-5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.	Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.

Collaborators and Investigators

• Sponsor: National Cancer Center, Korea
• Collaborators: Samsung Medical Center; Asan Medical Center; Seoul National University Hospital; Seoul National University Bundang Hospital; Hanyang University Guri Hospital
• Investigators: Principal Investigator: Bo Hyun Kim Kim, MD, National Cancer Center

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2028

Study Registration Dates

• First Submitted: December 9, 2025
• First Submitted That Met QC Criteria: December 9, 2025
• First Posted (Estimated): December 22, 2025

Study Record Updates

• Last Update Posted (Actual): January 7, 2026
• Last Update Submitted That Met QC Criteria: January 5, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Lenvatinib; child Pugh B
• Additional Relevant MeSH Terms: lenvatinib
• Other Study ID Numbers: NCC2025-0327

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No